Roquefort Therapeutics PLC Appointment of Joint Broker (0445T)
July 20 2022 - 2:00AM
UK Regulatory
TIDMROQ
RNS Number : 0445T
Roquefort Therapeutics PLC
20 July 2022
20 July 2022
Roquefort Therapeutics plc
("Roquefort Therapeutics" or the "Company")
Appointment of Joint Broker
Roquefort Therapeutics (LSE:ROQ,OTCQB:ROQAF), the Main Market
listed biotech company focused on early-stage opportunities in the
biotechnology sector, is pleased to announce the appointment of
Hybridan LLP ("Hybridan") as its Joint Broker with immediate
effect.
Stephen West, Roquefort Therapeutics Executive Chairman,
commented:
"We are delighted to be working with Hybridan going forward.
Hybridan has a deep understanding of the life sciences sector
particularly within small caps, and their experience will be
invaluable to Roquefort Therapeutics as we target further
institutional investors and family offices."
-Ends-
Enquiries:
Roquefort Therapeutics plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Hybridan LLP (Joint Broker)
Claire Louise Noyce
Optiva Securities Limited (Joint +44 (0)203 764
Broker) 2341
+44 (0)20 3411
Christian Dennis 1881
Buchanan (Public Relations)
Ben Romney / Jamie Hooper / George +44 (0)20 7466
Beale 5000
For further information on Roquefort Therapeutics, please visit
www.roquefortplc.com and @RoquefortTherap on Twitter.
LEI: 254900P4SISIWOR9RH34
About Roquefort Therapeutics
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF) is a Main Market
listed biotech company developing products through the pre-clinical
phase prior to partnering or selling to big pharma. The Company is
focused on developing first in class Midkine inhibiting drugs for
the treatment of cancer.
Through extensive research resulting in validation through
publication in over 1,000 scientific publications, Roquefort
Therapeutics has identified the potential to exploit the broad
therapeutic potential of Midkine for a number of clinical
indications of significant unmet needs. Roquefort Therapeutics
holds an exclusive licence to the largest global IP portfolio on
Midkine. The Midkine blocking drug development markets have
significant global market potential (in the multi-billion dollars).
Roquefort Therapeutics's pre-clinical programme is currently
underway with an initial focus on cancer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPDZGMNRLFGZZM
(END) Dow Jones Newswires
July 20, 2022 02:00 ET (06:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024